2) du Bois A, Luck HJ, Meier W et al : A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 : 1320-1329 (2003)
4) Parmar MK, Ledermann JA, Colombo Net al : ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375) : 2099-2106 (2003)
7) Boss EA, Massuger LF, Thomas CM et al : Vascular endothelial growth factor in ovarian cyst fluid. Cancer 91 : 371-377 (2001)
9) Zebrowski BK, Liu W, Ramirez K et al : Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6 : 373-378 (1999)
13) Aghajanian C, Finkler NJ, Rutherford, T. OCEANS : A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacitumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29 ASCO MEETING ABSTRACTS LBA5007 (2001)
14) Pujade-Lauraine E, Hilpert F, Weber B et al : AURELIA : A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT) -resistant recurrent ovarian cancer (OC). J Clin Oncol 30 ASCO MEETING ABSTRACTS May 30, 2012 : LBA5002 (2012)
17) Matulonis UA, Berlin S, Ivy P et al : Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27 : 5601-5606 (2009)
18) Hoffman-La Roche Limited. AVASTIN(R) product monograph. Mississauga, Ontario ; 26 August 2010.
22) Rudd ML, Price JC, Fogoros S et al : Aunique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17 (6) : 1331-1340 (2011)
24) Slomovitz BM, Lu KH, Johnston T et al : A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116 (23) : 5415-5419 (2010)
25) Slomovitz BM, Brown J, Johnston TA, et al : A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 29 : (2011) ASCO MEETING ABSTRACTS : LBA5012.
27) Monk BJ, Sill MW, Burger RA et al : Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix : a gynecologic oncology group study. J Clin Oncol 27 (7) : 1069-1074 (2009)
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (NCCNガイドラインの「ovarian cancer」【要登録】)